Search
01/01/2024
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, C, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1)DOI:10.17650/1726-9776-2024-20-1-24-35. PMID:. IF:(Q/D).
01/01/2024
Oncological results of salvage treatment in patients with oropharynx carcinoma treated with radiotherapy
León X., Neumann E., Holgado A., Vásquez R., Pujol A., Quer M.. Oncological results of salvage treatment in patients with oropharynx carcinoma treated with radiotherapy. Acta Otorrinolaringologica Espanola. 2024; 75(1)DOI:10.1016/j.otorri.2023.01.002. PMID:. IF:(Q/D).
01/01/2024
Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period
Benjumea, C, Navarro, F, Tarrés, CA. Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period. JOURNAL OF MEDICAL MICROBIOLOGY. 2024; 73(6)DOI:10.1099/jmm.0.001846. PMID:38935081. IF:2.000(Q3/8D).
01/01/2024
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).